Response Detection of Castrate-Resistant Prostate Cancer to Clinically Utilised and Novel Treatments by Monitoring Phospholipid Metabolism

<div>Mean <svg height="11.5564pt" id="M36" style="vertical-align:-2.26807pt" version="1.1" viewbox="-0.0498162 -9.28833 32.4083 11.5564" width="32.4083pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M300 -147C201 -63 143 98 143 270S200 602 300 686L282 710C136 610 70 450 70 271V270C70 89 136 -72 282 -170L300 -147Z" id="g113-41"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="346" vert-adv-y="346" xpluscharwidth="4.498"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,4.498,0)"><path d="M535 290V340H323V533H265V340H52V290H265V84H323V290H535ZM535 -22V28H52V-22H535Z" id="g117-37"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="587" vert-adv-y="587" xpluscharwidth="12.129000000000001"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,12.129,0)"><path d="M409 504C401 567 396 607 392 642C354 654 312 665 266 665C137 665 60 583 60 487C60 374 161 325 225 290C300 250 355 215 355 141C355 68 311 21 235 21C131 21 86 122 71 183L41 176C48 128 61 42 68 21C78 16 93 8 118 0C142 -7 175 -15 216 -15C349 -15 438 69 438 174C438 287 344 333 265 374C186 414 138 449 138 522C138 576 172 631 249 631C336 631 363 562 380 499L409 504Z" id="g121-81"></path><glyph.data ascent="989" descent="-360" horiz-adv-x="474" vert-adv-y="474" xpluscharwidth="18.291"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,18.134,0)"><path d="M43 650V622C120 616 128 612 128 526V124C128 39 120 33 34 27V0H270C392 0 492 25 567 83C643 141 690 230 690 350C690 444 655 517 605 565C543 625 450 650 323 650H43ZM213 547C213 587 217 598 226 604C236 612 262 617 304 617C371 617 429 604 474 576C554 529 592 439 592 336C592 176 505 36 319 36C246 36 213 55 213 131V547Z" id="g121-66"></path><glyph.data ascent="989" descent="-360" horiz-adv-x="735" vert-adv-y="735" xpluscharwidth="27.689"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,27.689,0)"><path d="M275 270C275 450 212 609 64 710L45 686C145 604 203 442 203 270S147 -63 45 -147L64 -170C213 -68 275 89 275 270Z" id="g113-42"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="346" vert-adv-y="346" xpluscharwidth="32.187"></glyph.data></g></svg>  <sup>31</sup>P-NMR spectroscopy detectable metabolite content (<i>µ</i>mol/mg protein) in control (untreated (black)), and pactitaxel (5 nM) (white), Epi-1 (40 <i>μ</i>M) (squares), or flutamide (20 <i>μ</i>M) (diagonal) treated LNCaP cells.</div>

BioMed Research International

fig5

Figure 5

Figure 5: Response Detection of Castrate-Resistant Prostate Cancer to Clinically Utilised and Novel Treatments by Monitoring Phospholipid Metabolism 